Cadence Neuroscience is moving to bring a neuromodulation therapy for patients with focal drug-resistant epilepsy to market. The Redmond, WA-based company has raised $15 million in a series A round to help with this goal.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,